A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.

Although most pituitary tumors are benign, some are invasive or aggressive. In the absence of specific markers of malignancy, only tumors with metastases are considered malignant. To identify markers of invasion and aggressiveness, we focused on prolactin (PRL) tumors in the human and rat. Using radiology and histological methods, we classified 25 human PRL tumors into three groups (non-invasive, invasive, and aggressive-invasive) and compared them with a model of transplantable rat PRL tumors with benign and malignant lineages. Combining histological(mitoses and labeling for Ki-67, P53, pituitary transforming tumor gene (PTTG), and polysialic acid neural cell adhesion molecule) and transcriptomic (microarrays and q-RTPCR) methods with clinical data (post-surgical outcome with case-control statistical analysis), we found nine genes implicated in invasion (ADAMTS6, CRMP1, and DCAMKL3) proliferation (PTTG, ASK, CCNB1, AURKB, and CENPE), or pituitary differentiation (PITX1) showing differential expression in the three groups of tumors (P = 0.015 to 0.0001). A case-control analysis, comparing patients in remission (9 controls) and patients with persistent or recurrent tumors (14 cases) revealed that eight out of the nine genes were differentially up- or downregulated (P = 0.05 to 0.002), with only PTTG showing no correlation with clinical course (P = 0.258). These combined histological and transcriptomic analyses improve the pathological diagnosis of PRL tumors, indicating a reliable procedure for predicting tumor aggressiveness and recurrence potential. The similar gene profiles found between non-invasive human and benign rat tumors, as well as between aggressive-invasive human and malignant rat tumors provide new insights into malignancy in human pituitary tumors.

[1]  N. Karavitaki,et al.  What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. , 2007, European journal of endocrinology.

[2]  W. Farrell,et al.  Pituitary tumours: findings from whole genome analyses. , 2006, Endocrine-related cancer.

[3]  C. Mottolese,et al.  Microarray Analysis Reveals Differential Gene Expression Patterns in Tumors of the Pineal Region , 2006, Journal of neuropathology and experimental neurology.

[4]  C. Croce,et al.  HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. , 2006, Cancer cell.

[5]  Gavin D. Grant,et al.  Common markers of proliferation , 2006, Nature Reviews Cancer.

[6]  Xianquan Zhan,et al.  Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. , 2005, Cancer research.

[7]  R. Booton,et al.  Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability , 2005, British Journal of Cancer.

[8]  S. Czirják,et al.  Differential gene expression in pituitary adenomas by oligonucleotide array analysis. , 2005, European journal of endocrinology.

[9]  R. Bernards,et al.  A Genetic Screen Identifies PITX1 as a Suppressor of RAS Activity and Tumorigenicity , 2005, Cell.

[10]  M. Buchfelder,et al.  Diagnosis and Management of Pituitary Carcinomas , 2005 .

[11]  G. Sassolas,et al.  Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance , 2005, Acta Neurochirurgica.

[12]  D. Edwards,et al.  The ADAMTS metalloproteinases. , 2005, The Biochemical journal.

[13]  J. Labbé,et al.  Kinetochore localization of spindle checkpoint proteins: who controls whom? , 2004, Molecular biology of the cell.

[14]  A. Almasan,et al.  Opposing roles of E2Fs in cell proliferation and death , 2004, Cancer biology & therapy.

[15]  Yung-Ming Jeng,et al.  Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. , 2004, Journal of the National Cancer Institute.

[16]  J. Swedlow,et al.  Mitotic mechanics: the auroras come into view. , 2003, Current opinion in cell biology.

[17]  Jiandong Chen,et al.  Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. , 2003, Endocrinology.

[18]  A. Tabarin,et al.  Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. , 2003, Journal of neurosurgery.

[19]  B. Scheithauer,et al.  Differential expression of galectin-3 in pituitary tumors. , 2003, Cancer research.

[20]  Joseph B. Rayman,et al.  E2F4 loss suppresses tumorigenesis in Rb mutant mice. , 2002, Cancer cell.

[21]  V. Esposito,et al.  A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. , 2002, Endocrine-related cancer.

[22]  E. Laws,et al.  The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. , 2002, Journal of neurosurgery.

[23]  D. Brat,et al.  Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. , 2001, The Journal of clinical endocrinology and metabolism.

[24]  A. Harris,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior , 2000 .

[25]  Yun Zheng,et al.  CENP-E forms a link between attachment of spindle microtubules to kinetochores and the mitotic checkpoint , 2000, Nature Cell Biology.

[26]  J. Honnorat,et al.  Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes , 1999, The European journal of neuroscience.

[27]  S. Melmed,et al.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis , 1999, Nature Medicine.

[28]  H. Mukhtar,et al.  Upregulation of E2F transcription factors in chemically induced mouse skin tumors. , 1999, International journal of oncology.

[29]  H. Katayama,et al.  Mitotic kinase expression and colorectal cancer progression. , 1999, Journal of the National Cancer Institute.

[30]  S. Melmed,et al.  Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. , 1999, The Journal of clinical endocrinology and metabolism.

[31]  S. Asa,et al.  The cytogenesis and pathogenesis of pituitary adenomas. , 1998, Endocrine reviews.

[32]  C. Lanctôt,et al.  The pan-pituitary activator of transcription, Ptx1 (pituitary homeobox 1), acts in synergy with SF-1 and Pit1 and is an upstream regulator of the Lim-homeodomain gene Lim3/Lhx3. , 1998, Molecular endocrinology.

[33]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[34]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.

[35]  D. Ray,et al.  Pituitary cytokine and growth factor expression and action. , 1997, Endocrine reviews.

[36]  S. Melmed,et al.  Isolation and characterization of a pituitary tumor-transforming gene (PTTG). , 1997, Molecular endocrinology.

[37]  S. Tsuji,et al.  Characterization of Mouse ST8Sia II (STX) as a Neural Cell Adhesion Molecule-specific Polysialic Acid Synthase , 1996, The Journal of Biological Chemistry.

[38]  S. Lightman,et al.  p53 gene mutations in pituitary adenomas: rare events , 1994, Clinical endocrinology.

[39]  B. Scheithauer,et al.  H-ras mutations in human pituitary carcinoma metastases. , 1994, The Journal of clinical endocrinology and metabolism.

[40]  E. Hedley‐Whyte,et al.  Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. , 1993, Journal of neurosurgery.

[41]  B. Claustrat,et al.  Spontaneous prolactin transplantable tumor in the Wistar/Furth rat (SMtTW): a new animal model of human prolactinoma. , 1990, Cancer research.

[42]  E. Knosp,et al.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. , 1989, Neurosurgery.

[43]  M. Buchfelder,et al.  Clinical review: Diagnosis and management of pituitary carcinomas. , 2005, The Journal of clinical endocrinology and metabolism.

[44]  D. Figarella-Branger,et al.  The new WHO classification of human pituitary tumors: comments , 2005, Acta Neuropathologica.

[45]  A. Grossman.  The 2004 World health organization classification of pituitary tumors: is it clinically helpful? , 2005, Acta Neuropathologica.

[46]  S. Melmed,et al.  2004 World Health Organization classification of pituitary tumors: what is new? , 2005, Acta Neuropathologica.

[47]  S. Asa,et al.  The 2004 World Health Organization classification of pituitary tumors: What is new? , 2005, Acta Neuropathologica.

[48]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[49]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[50]  Gillian E. Wu,et al.  Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. , 2002, The Journal of clinical investigation.

[51]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[52]  B. Tang,et al.  ADAMTS: a novel family of extracellular matrix proteases. , 2001, The international journal of biochemistry & cell biology.

[53]  D. Figarella-Branger,et al.  Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy. , 2000, Cancer research.

[54]  B. Scheithauer,et al.  Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas , 1999, Endocrine pathology.

[55]  E. Hooghe-Peters,et al.  Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression. , 1999, Endocrinology.